Partnerships

Alloy Therapeutics has developed several strains of immunocompetent transgenic mice, allowing for best-in-class in vivo human antibody technology, and offers it for diverse and non-exclusive use.

OmniAb^® provides therapeutic antibody platforms that produce highly diversified, fully human antibody repertoires optimized in vivo for manufacturability, therapeutic efficacy and reduced immunogenicity.

Leveragen has developed a next-generation fully human single-domain antibody model, the Singularity Sapiens Mouse, which exclusively generates heavy-chain antibodies from the complete human VH repertoire integrated into the mouse Igh locus. This targeted approach ensures the faithful expression of human immunoglobulin genes, eliminates interfering conventional antibodies, and promotes optimal B cell development and robust immune responses.

Atlas™ Mouse Technologies from AbTherx feature three models – the Full Human Diversity Mouse, Binary Fixed Light Chain Mouse, and Long CDR3 Mouse – that give antibody discovery teams novel approaches to address some of the challenges inherent in traditional transgenic platforms, including royalty- and milestone-free licensing options. 

Cyagen’s HUGO-Ab™ Mouse Models leverage the company’s proprietary TurboKnockout^® ESC-mediated gene targeting to humanize the VH and VL genes in situ, offering more stable phenotypic and functional outcomes than traditional transgenic methods, and substitute an up-front payment for royalties and/or milestone payments.